Page 7 - Vaccine

WHO hopes to bring countries together on reinforcing pandemic preparedness

The World Health Organisation begins its annual meeting on Monday with government ministers and other top envoys hoping to reinforce global preparedness for the next pandemic in the devastating wake of COVID-19. But the most ambitious project, to adopt a pandemic treaty, has been shelved for now after 2 1/2 years of work failed to produce a draft that countries could unite behind by Friday, as originally hoped. WHO Director-General Tedros Adhanom Ghebreyesus insists it's not a failure and the World Health Assembly this week can still plot the way forward. When diplomats, health officials and activists were still attempting to produce a draft treaty, he predicted the assembly could be one of the most significant in WHO's 76-year history. Not anymore. WHO officials and others have been eager to build on the momentum of concern from the coronavirus pandemic, with the risk that the more it fades into history, the less the public and policymakers will be interested in preparing for a

Non-profit criticises ICMR for rejecting Covaxin study, alleges censorship

Researchers associated with Banaras Hindu University have said Bharat Biotech's Covid-19 vaccine has side effects in children

Serum Institute ships its first set of malaria vaccine doses to Africa

The vaccine has been developed in collaboration with the University of Oxford and Novavax's Matrix-M adjuvant

BHU study on Covaxin side effects poorly designed: ICMR director Bahl

The Indian Council of Medical Research Director General Dr Rajiv Bahl on Monday criticised a recently published study on the long-term safety analysis of the Covaxin in adults and adolescents for its poor methodology and design, and clarified the article misleadingly and erroneously "acknowledges" ICMR. Dr Bahl said the study had no control arm of unvaccinated individuals for comparing the rates of events between the vaccinated and unvaccinated groups. Hence, the reported events in the study cannot be linked or attributed to COVID-19 vaccination. The ICMR is not associated with the study and has not provided any financial or technical support for the research, Dr Bahl said. The ICMR DG has written a letter to the authors of the paper and Editor of the journal to immediately remove the acknowledgement to ICMR and publish an erratum. A research paper, titled 'Long-Term Safety Analysis of the BBVl52 Coronavirus Vaccine in Adolescents and Adults: Findings from a l-Year Prospective Stud

SII to acquire 20% stake in needle-free tech company IntegriMedical

The collaboration leverages SII's manufacturing and distribution strength with IntegriMedical's innovative technology

Covaxin has 'excellent record', says Bharat Biotech after study cites risks

The research conducted by BHU indicated that Covaxin increased the rare risk of stroke and Guillain-Barre syndrome, among other issues

After Covishield, new study 'finds' side effects in Covaxin recipients

In observational study on Bharat Biotech's Covaxin recipients, about one-third of participants reported adverse events

12% of India's eligible children received no dose of measles vaccine: Study

Nearly 12 per cent of children in India who are eligible for measles vaccination have received none of the recommended double-dose, signalling a "concerning gap" in immunisation coverage, a new study has found. The findings showed that zero-dose cases were high in the northeastern states, with Nagaland reporting the greatest share at 26 per cent. Tamil Nadu was found to report the lowest at 4.6 per cent. Researchers from the Ministry of Health and Family Welfare and Banaras Hindu University in Varanasi investigated previously overlooked critical aspects of measles vaccination, focusing on zero-doses, partially vaccinated, and those fully immunised. They analysed data of over 43,000 children aged 2-3 years, collected through the National Family Health Survey 2019-21 (NFHS-5). The team found that close to 30 per cent of the eligible children have received only one measles-containing vaccine (MCV1), while about 60 per cent have been fully immunised (MCV2). The findings are published in

Not producing, distributing Covishield since December 2021: Serum Institute

AstraZeneca Covid vaccine row: As of April 30, 2024, over 1.7 billion doses of the Covishield vaccine has been administered in India

SC to hear Serum's plea challenging amendment to IT Act on May 17

With this plea, it also challenged the Bombay High Court's order that dismissed its petition against a 2016 amendment to the Income Tax Act

U-WIN may allow mothers to track and report vaccine side-effects on babies

Similar to the CoWIN portal for covid-19, the government's U-WIN platform registers and tracks routine vaccination and immunisation

Covishield vaccine case: Plea filed in SC seeking probe on AstraZeneca

AstraZeneca, facing a lawsuit in UK for alleged vaccine-related deaths and injuries, has acknowledged that its vaccine can cause Thrombosis with Thrombocytopenia Syndrome (TTS)

AstraZeneca responds to Covishield vaccine concerns: Here's what they said

Regulatory agencies around the world maintain that the risks from the vaccine outweigh the benefits

AstraZeneca's Covishield causes rare blood clot disorder TTS: What is it?

Covishield, a vaccine developed by AstraZeneca and Oxford University and manufactured by the Serum Institute of India, can, in rare instances, lead to TTS

Bharat Biotech co-founder Krishna Ella takes helm as President of IVMA

Ella takes over the presidency from Adar C Poonawalla, who held the post from 2019 to March 2024

Healthcare solution provider Enhanced Innovations launches 'Phloton'

A portable cold chain solution for last-mile vaccine delivery

Bharat Biotech, Bilthoven Biologicals collaborate for oral polio vaccines

Bilthoven Biologicals will produce the vaccines for distribution in India and worldwide

Dr Reddy's partners with Sanofi India to distribute vaccine brands in India

Under the terms of this agreement, Dr Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands, including Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri and Adacel

Bharat Biotech's TB vaccine MTBVAC begins clinical trials in India

The trials will assess the vaccine's safety, immune response, and efficacy in preventing TB in adults and adolescents. MTBVAC has been developed after research spanning over three decades

IVI commences tech transfer of oral cholera vaccine to Biological E

The tech transfer will be completed by 2025 and the vaccine will be manufactured for India and international markets by Biological E